Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Over the last 7 days, the United States market has dropped 2.4%, though it has risen by 22% over the past year, with earnings forecasted to grow by 18% annually. In this context, identifying stocks that might be trading below their estimated intrinsic value can present potential opportunities for investors looking to capitalize on undervalued assets.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Wealthfront (WLTH) $8.82 $17.14 48.5% Rayonier (RYN) $20.86 $40.73 48.8% Procore Technologies (PCOR) $42.20 $81.28 48.1% Live Oak Bancshares (LOB) $38.66 $74.21 47.9% Kingstone Companies (KINS) $15.88 $31.31 49.3% Inter & Co (INTR) $5.71 $11.10 48.5% Dana (DAN) $30.11 $59.53 49.4% Clear Secure (YOU) $51.00 $100.74 49.4% Alkami Technology (ALKT) $14.91 $29.64 49.7% AbbVie (ABBV) $224.77 $440.86 49%

Click here to see the full list of 131 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Space Exploration Technologies

Overview: Space Exploration Technologies Corp. offers satellite-based broadband services across the United States, Ireland, Canada, and internationally, with a market cap of approximately $1.77 trillion.

Operations: The company's revenue segments include $3.29 billion from AI, $3.84 billion from Space, and $12.17 billion from Connectivity services.

Estimated Discount To Fair Value: 36.9%

Space Exploration Technologies, recently completing a US$75 billion IPO, shows potential undervaluation based on cash flows with shares trading significantly below estimated future cash flow value. Despite high operational costs linked to AI infrastructure expansion, notable deals with Google and Anthropic promise substantial revenue streams. The company's projected 41.8% annual revenue growth outpaces the market average, positioning it for profitability within three years amidst its strategic pivot towards AI data centers and satellite infrastructure projects.

According our earnings growth report, there's an indication that Space Exploration Technologies might be ready to expand. Click here to discover the nuances of Space Exploration Technologies with our detailed financial health report.SPCX Discounted Cash Flow as at Jun 2026

Boeing

Overview: The Boeing Company, along with its subsidiaries, engages in the design, development, manufacturing, sale, servicing, and support of commercial jetliners and military aircraft as well as satellites and space systems globally; it has a market cap of approximately $164.76 billion.

Operations: Boeing's revenue segments consist of Commercial Airplanes at $42.55 billion, Defense, Space & Security at $28.54 billion, and Global Services at $21.23 billion.

Story Continues

Estimated Discount To Fair Value: 39.8%

Boeing is trading at US$221.63, significantly below its estimated future cash flow value of US$367.97, highlighting potential undervaluation. Forecasted annual earnings growth of 38.7% surpasses the US market average, though revenue growth lags behind at 9.7%. Recent strategic partnerships and aircraft deliveries enhance Boeing's operational capabilities and market reach but debt coverage by operating cash flow remains a concern, impacting its financial position despite profitability achieved this year.

Insights from our recent growth report point to a promising forecast for Boeing's business outlook. Take a closer look at Boeing's balance sheet health here in our report.BA Discounted Cash Flow as at Jun 2026

York Space Systems

Overview: York Space Systems, Inc. is a space and defense company offering mission-critical solutions for national security, government, and commercial clients in the United States with a market cap of $3.58 billion.

Operations: The company's revenue is derived entirely from its Aerospace & Defense segment, which generated $396.29 million.

Estimated Discount To Fair Value: 11.6%

York Space Systems, trading at US$33.72, is undervalued relative to its estimated cash flow value of US$38.15. Despite a volatile share price, its revenue growth forecast of 27.2% per year outpaces the US market average and it is expected to become profitable within three years. Recent achievements include completing two production lots for national security spacecraft, showcasing operational efficiency and capability in high-rate manufacturing crucial for space-based defense infrastructures.

Upon reviewing our latest growth report, York Space Systems' projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of York Space Systems stock in this financial health report.YSS Discounted Cash Flow as at Jun 2026

Seize The Opportunity

Dive into all 131 of the Undervalued US Stocks Based On Cash Flows we have identified here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Curious About Other Options?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SPCXBA and YSS.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Key Points

The company is expanding both approved and pipeline therapies. New indications could expand the market for existing drugs. Long-term cash flow growth could support future dividend increases.10 stocks we like better than AbbVie ›

AbbVie (NYSE: ABBV) boasts a pretty attractive dividend at more than 3%.

That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and Amgen (NASDAQ: AMGN), all of which yield dividends of roughly 2% or less.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

But dividends don't increase just because management wants them to. They rise because the business generates enough cash to support them.

Following the money

This week, AbbVie presented new data from its blood cancer portfolio at the European Hematology Association (EHA) Congress.

This is one of the world's largest medical conferences focused on blood cancers and disorders, bringing together thousands of physicians, researchers, pharmaceutical companies, and healthcare professionals to present new clinical trial data and discuss emerging treatments.

The reason EHA is important is that companies often use the conference to release new data on cancer drugs, particularly therapies targeting blood cancers. Positive results presented at EHA can support regulatory approvals, label expansions, partnerships, and future revenue growth. That's why AbbVie showcased its new clinical results there.

The company's most recent presentations included data on approved therapies as well as several pipeline candidates. In total, AbbVie showcased 21 presentations spanning multiple blood cancers, including chronic lymphocytic leukemia, follicular lymphoma, multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma.

AbbVie generated about $61 billion in revenue during 2025, and while immunology drugs receive most of the attention, oncology remains an important contributor.

The company's oncology portfolio generated about $6.7 billion in revenue in 2025. That's not insignificant.

That revenue helps fund research and development, debt reduction, share repurchases, and dividends.

Indeed, oncology helps diversify AbbVie's business.

Diversifying the pipeline

You may remember the company's dependence on Humira.

At its peak, Humira was one of the best-selling drugs in pharmaceutical history, generating about $21 billion in annual revenue.

That concentration created a significant risk because patents eventually expire. And when Humira lost U.S. exclusivity in 2023, and biosimilar generics entered the market, Humira revenue began declining rapidly.

Management saw this challenge coming years in advance and responded by aggressively building new growth platforms across immunology, oncology, and neuroscience.

Image source: Getty Images.

Today, drugs such as Skyrizi and Rinvoq (used to treat Crohn's disease, ulcerative colitis, and arthritis) are helping offset Humira's decline, while the company's oncology portfolio provides another important source of revenue and cash flow. The result is a much more diversified business than just a few years ago.

Today, AbbVie generates revenue across immunology, neuroscience, and oncology. That has reduced dependence on any single product and created a more resilient cash flow profile.

And that's why the EHA presentations are relevant.

AbbVie is actively expanding the use of existing drugs while advancing newer therapies that could eventually offset declines from older products. The company highlighted encouraging efficacy data across multiple studies, including late-stage programs and investigational treatments targeting difficult-to-treat blood cancers.

Of course, you can't guarantee successful drug development.

Clinical setbacks happen, and not every program succeeds. It's just part of the overall process of developing new therapies.

Still, AbbVie's oncology portfolio is no longer dependent on a single drug. The company now has multiple approved products, several late-stage opportunities, and a broader pipeline than it did just a few years ago.

Now consider that the latest clinical updates will strengthen the revenue engine supporting the dividend over the long term.

AbbVie's oncology business already generates billions of dollars annually, and management continues working to ensure that oncology remains a growth driver rather than a mature business.

That's why the company continues investing heavily in expanding existing therapies into new indications while advancing next-generation treatments for blood cancers and solid tumors.

Every successful clinical trial creates the potential for new approvals, larger patient populations, and longer revenue runways. And because cancer treatments often command premium pricing and can remain on the market for many years, successful oncology drugs can become meaningful cash-generating assets.

And ultimately, it's cash flow that pays dividends.

Should you buy stock in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!

Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of June 12, 2026.

Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with anticipated earnings growth of 18% per annum in the coming years. In this fluctuating environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Western Digital (WDC) $490.09 $963.12 49.1% Solstice Advanced Materials (SOLS) $77.69 $154.41 49.7% Rayonier (RYN) $20.69 $40.79 49.3% MercadoLibre (MELI) $1588.29 $3090.91 48.6% Live Oak Bancshares (LOB) $38.21 $74.21 48.5% Kingstone Companies (KINS) $15.84 $31.31 49.4% Gold Royalty (GROY) $2.70 $5.32 49.2% Bowhead Specialty Holdings (BOW) $27.08 $52.60 48.5% Alkami Technology (ALKT) $15.01 $29.64 49.4% AbbVie (ABBV) $224.95 $440.96 49%

Click here to see the full list of 139 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

First Community

Overview: First Community Corporation, with a market cap of $298.10 million, operates as the bank holding company for First Community Bank, offering a range of commercial and retail banking products and services to small-to-medium sized businesses, professionals, and individuals.

Operations: The company generates revenue through several segments, including Commercial and Retail Banking ($65.40 million), Mortgage Banking ($9.49 million), Investment Advisory and Non-Deposit services ($8.03 million), and the Corporate Segment ($6.81 million).

Estimated Discount To Fair Value: 35.1%

First Community Corporation appears undervalued, trading at 35.1% below its estimated fair value and over 20% below its future cash flow value. The company reported net interest income of US$18.37 million for Q1 2026, with net income rising to US$5.5 million from the previous year. Despite recent shareholder dilution, earnings are forecast to grow significantly at over 20% annually, supported by a share repurchase program worth up to US$7.5 million expiring in May 2027.

According our earnings growth report, there's an indication that First Community might be ready to expand. Click to explore a detailed breakdown of our findings in First Community's balance sheet health report.FCCO Discounted Cash Flow as at Jun 2026

Chemung Financial

Overview: Chemung Financial Corporation is a bank holding company for Chemung Canal Trust Company, offering various banking, financing, fiduciary, and financial services with a market cap of $344.47 million.

Story Continues

Operations: The company's revenue segments include Core Banking at $84.59 million and Wealth Management Group (WMG) at $12.22 million, with adjustments from Holding Company and Cfs Group, Inc. (CFS) accounting for -$1.44 million.

Estimated Discount To Fair Value: 27.6%

Chemung Financial is trading at US$72.23, below its estimated future cash flow value of US$99.77, suggesting undervaluation. Earnings are projected to grow significantly at 35% annually, outpacing the broader US market's growth forecast. Despite insider selling and moderate revenue growth expectations of 17.6%, recent earnings reports show strong performance with net income rising to US$9.2 million for Q1 2026 from the previous year’s US$6.02 million, supporting its investment appeal based on cash flows.

Our growth report here indicates Chemung Financial may be poised for an improving outlook. Delve into the full analysis health report here for a deeper understanding of Chemung Financial.CHMG Discounted Cash Flow as at Jun 2026

Consolidated Water

Overview: Consolidated Water Co. Ltd., operating through its subsidiaries, supplies potable water, treats wastewater, and offers water-related products and services across the Cayman Islands, the Bahamas, the United States, and the British Virgin Islands with a market cap of $482.57 million.

Operations: Consolidated Water's revenue segments are comprised of Bulk ($33.81 million), Retail ($32.75 million), Manufacturing ($14.28 million), and Services Excluding Manufacturing ($47.49 million).

Estimated Discount To Fair Value: 17.5%

Consolidated Water, priced at US$30.09, trades below its estimated future cash flow value of US$36.48, indicating potential undervaluation based on cash flows. While earnings grew 10.4% last year and are forecast to grow 19.9% annually, revenue is expected to rise 24.5%, surpassing market averages. Recent strategic hires and expansion plans in desalination and water infrastructure signal growth opportunities despite a slight decline in Q1 earnings compared to the previous year.

The analysis detailed in our Consolidated Water growth report hints at robust future financial performance. Take a closer look at Consolidated Water's balance sheet health here in our report.CWCO Discounted Cash Flow as at Jun 2026

Where To Now?

Discover the full array of 139 Undervalued US Stocks Based On Cash Flows right here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready To Venture Into Other Investment Styles?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include FCCOCHMG and CWCO.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

AbbVie ABBV continues to see strong momentum from Skyrizi and Rinvoq, its two blockbuster immunology medicines. Sales of both drugs not only mitigated the impact of continued erosion in legacy drug Humira but also reaffirmed their role as AbbVie's key growth drivers.

This growth continued into 2026. In the first quarter, Skyrizi sales increased 29.2% year over year to $4.48 billion, while Rinvoq sales rose 20.2% to $2.12 billion. Together, the products were key contributors to AbbVie's double-digit revenue growth in the quarter. The company subsequently raised its 2026 revenue outlook for both medicines by $100 million each and now expects Skyrizi and Rinvoq to generate $21.6 billion and $10.2 billion in sales, respectively, this year. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026.

A key driver behind this strength is continued demand across inflammatory bowel disease (IBD) indications, including ulcerative colitis (UC) and Crohn's disease (CD). Skyrizi has emerged as a leading therapy in the category, while Rinvoq continues to gain traction following label expansions that support earlier use in treatment. AbbVie also highlighted continued market-share gains and strong new-patient demand for both products in the first quarter.

The growth runway for both medicines remains substantial. AbbVie recently submitted regulatory applications seeking approval of Rinvoq across two indications — vitiligo and alopecia areata — and Skyrizi as a subcutaneous induction option for CD. Additional growth opportunities remain, with Rinvoq being evaluated in late-stage studies for hidradenitis suppurativa and systemic lupus erythematosus, and data readouts expected later this year. Management believes the next wave of Rinvoq indications alone could contribute roughly $2 billion in peak annual sales. Combined with continued market-share gains across psoriasis and IBD, these label expansion opportunities should support sustained growth for both medicines through 2026 and beyond.

ABBV's Competition in the Immunology Space

Johnson & Johnson JNJ remains one of AbbVie's strongest competitors in immunology through blockbuster medicines Tremfya and Stelara. While Stelara faces biosimilar competition, J&J continues to strengthen its position with Tremfya, which is approved across multiple immunology indications, including UC and CD. The company also recently gained FDA approval for Icotyde, a new oral immunology therapy that is positioned as a direct competitor to Skyrizi.

Story Continues

Eli Lilly LLY is also expanding its presence in the immunology space. Its IL-23 inhibitor Omvoh is approved for both UC and CD, broadening Eli Lilly's footprint in the fast-growing IBD market.

ABBV's Price Performance, Valuation and Estimates

Shares of AbbVie have underperformed the industry year to date, as seen in the chart below.Zacks Investment Research

Image Source: Zacks Investment Research

From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.81 times forward earnings compared with the industry's average of 17.67.Zacks Investment Research

Image Source: Zacks Investment Research

Revisions in EPS estimates for 2026 and 2027 have trended higher over the past 30 days.Zacks Investment Research

Image Source: Zacks Investment Research

AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Johnson & Johnson (JNJ) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Over the last 7 days, the United States market has experienced a 4.1% drop, although it remains up by 21% over the past year with earnings forecasted to grow by 18% annually. In such fluctuating conditions, identifying stocks that might be undervalued based on current market estimates can present opportunities for investors seeking potential growth at a reasonable price.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Western Digital (WDC) $490.09 $963.12 49.1% Solstice Advanced Materials (SOLS) $77.69 $154.41 49.7% Rayonier (RYN) $20.69 $40.79 49.3% MercadoLibre (MELI) $1588.29 $3090.91 48.6% Live Oak Bancshares (LOB) $38.21 $74.21 48.5% Kingstone Companies (KINS) $15.84 $31.31 49.4% Gold Royalty (GROY) $2.70 $5.32 49.2% Bowhead Specialty Holdings (BOW) $27.08 $52.60 48.5% Alkami Technology (ALKT) $15.01 $29.64 49.4% AbbVie (ABBV) $224.95 $440.96 49%

Click here to see the full list of 139 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

Mission Produce

Overview: Mission Produce, Inc. is involved in the sourcing, farming, packaging, marketing, and distribution of avocados, mangoes, and blueberries to food retailers, wholesalers, and foodservice customers both in the United States and internationally with a market cap of approximately $960.04 million.

Operations: The company's revenue is primarily derived from its Marketing & Distribution segment at $1.13 billion, followed by International Farming at $126.90 million, and Blueberries contributing $92.80 million.

Estimated Discount To Fair Value: 25.9%

Mission Produce is trading at US$11.24, below its estimated future cash flow value of US$15.17, suggesting it might be undervalued based on cash flows. Despite recent net losses and reduced profit margins, analysts forecast significant annual earnings growth of 82.3% over the next three years, outpacing the broader market's expected growth rate. The company has initiated a share repurchase program worth up to US$100 million, indicating confidence in its intrinsic value despite current challenges.

Insights from our recent growth report point to a promising forecast for Mission Produce's business outlook. Unlock comprehensive insights into our analysis of Mission Produce stock in this financial health report.AVO Discounted Cash Flow as at Jun 2026

OceanFirst Financial

Overview: OceanFirst Financial Corp. is the bank holding company for OceanFirst Bank N.A., with a market cap of $1.04 billion.

Operations: OceanFirst Bank N.A. generates revenue primarily through its Community Banking Services segment, which accounted for $396.65 million.

Story Continues

Estimated Discount To Fair Value: 38.4%

OceanFirst Financial, trading at US$18.29, is undervalued relative to its estimated future cash flow value of US$29.71 and offers a reliable 4.37% dividend yield. The company's earnings are forecast to grow significantly at 55.5% annually, outpacing the broader U.S. market's growth expectations. Recent merger with Flushing Financial Corporation expands its board and strategic capabilities, while shelf registrations indicate plans for capital raising amidst robust revenue growth projections of 35% per year.

Upon reviewing our latest growth report, OceanFirst Financial's projected financial performance appears quite optimistic. Take a closer look at OceanFirst Financial's balance sheet health here in our report.OCFC Discounted Cash Flow as at Jun 2026

On Holding

Overview: On Holding AG, with a market cap of $12.66 billion, develops and distributes performance sports products under the On brand across Switzerland, Europe, the Middle East, Africa, the United States, the Americas, and Asia-Pacific.

Operations: The company's revenue primarily comes from its Athletic Footwear segment, which generated CHF 3.12 billion.

Estimated Discount To Fair Value: 28.9%

On Holding, trading at US$38, is undervalued compared to its estimated future cash flow value of US$53.47. Earnings are projected to grow significantly at 23.2% annually, surpassing the U.S. market's expectations. Recent guidance indicates net sales growth of at least 23% year-over-year in constant currency terms for 2026, with reported net sales expected to reach CHF 3.51 billion. Leadership changes aim to enhance strategic execution as co-founders assume Co-CEO roles for global expansion.

Our growth report here indicates On Holding may be poised for an improving outlook. Dive into the specifics of On Holding here with our thorough financial health report.ONON Discounted Cash Flow as at Jun 2026

Where To Now?

Click this link to deep-dive into the 139 companies within our Undervalued US Stocks Based On Cash Flows screener. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Searching for a Fresh Perspective?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AVOOCFC and ONON.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

ANI Pharmaceuticals ANIP is executing a clear pivot toward higher-margin specialty revenues, led by Purified Cortrophin Gel. That momentum is now showing up in earnings power and a higher 2026 outlook.

The debate is whether that upside is strong enough to offset two real risks: intensifying competition in key markets and meaningful customer concentration. That tradeoff frames the rest of the setup.

ANIP’s Setup: Growth Engine vs. Risk Factors

Cortrophin Gel has become the company’s primary growth engine, driving the Rare Disease franchise and pushing the mix toward specialty therapies. In 2025, Cortrophin delivered $347.8 million in revenue, up about 76% year over year, and management expects that strength to continue in 2026 with sales guidance of $540-$575 million. The company is also investing behind adoption, including a dedicated ~90-person sales force focused on acute gouty arthritis flares and a prefilled syringe formulation that has already become the majority of new patient starts.

The key offsets are competition and concentration. In retina, the Iluvien franchise faces entrenched alternatives from larger players. AbbVie ABBV markets Ozurdex, which competes across diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment, while Regeneron Pharmaceuticals REGN remains a major force in diabetic macular edema through Eylea and Eylea HD. On the distribution side, three wholesale customers represented 53% of 2025 net revenue and 64% of accounts receivable, which can amplify pricing pressure if purchasing leverage increases.

ANI Pharmaceuticals’ 2026 Guidance

After the strong first quarter, ANI raised its full-year 2026 total net revenue outlook by $25 million to $1.08-$1.14 billion. It also lifted adjusted EBITDA guidance by $10 million to $285-$300 million and raised adjusted earnings per share to $9.19-$9.69 from $8.83-$9.34.

Importantly, the company reaffirmed product-level expectations for both key branded drivers. Cortrophin Gel remained guided to $540-$575 million, and Iluvien was reaffirmed at $78-$83 million, which implies a return to growth versus 2025.

Management tied the higher full-year outlook to two drivers: stronger-than-expected Generics performance exiting the first quarter and improved visibility into upcoming launches for the remainder of 2026. That combination matters because it supports the idea that the guidance raise was not solely a one-quarter timing benefit.

ANIP’s Q1 2026 Performance as a Validation Point

First-quarter 2026 results provided a clean validation point. Adjusted earnings per share came in at $2.05, up nearly 21% year over year and well ahead of the $1.28 consensus estimate. Revenue was $237.5 million, up 20.5% year over year and above the $205.4 million consensus estimate.

Story Continues

Two items stood out in the quarter. First, Cortrophin maintained strong momentum, with net revenue rising 42% to $75.1 million. Second, ANI benefited from a newly monetized intellectual property licensing arrangement that added meaningful royalties and other revenue.

Rare Disease and Brands net revenue grew 36% to $128.2 million, supported by both Cortrophin and Iluvien, with Iluvien sales up 19.5% to $19.3 million. The mix also shifted as the company recorded $21.5 million in brand royalties and other revenues tied to the Harmony Biosciences HRMY licensing agreement, including a $15 million upfront fee and early royalty income.

ANI Pharmaceuticals, Inc. PriceANI Pharmaceuticals, Inc. Price

ANI Pharmaceuticals, Inc. price | ANI Pharmaceuticals, Inc. Quote

ANI Pharmaceuticals’ Cash, Leverage and Flexibility

ANI ended March 31, 2026 with $311.2 million in unrestricted cash and cash equivalents, up from $285.6 million at the end of 2025. Operating cash flow was $58.4 million in the quarter, reflecting the improved earnings profile and working-capital dynamics.

Debt remains meaningful but structured in a way management frames as manageable. As of quarter-end, ANI reported $625 million in principal value of outstanding debt, including senior convertible notes and a term loan. Management cited gross leverage of 2.6x and net leverage of 1.3x based on trailing 12-month adjusted non-GAAP EBITDA of $242 million.

That balance sheet profile supports continued investment in the Rare Disease buildout and leaves room for potential inorganic opportunities, which the company has highlighted as part of its broader growth approach.

ANIP’s Share Repurchase Program and Capital Allocation

Alongside the guidance raise, ANI authorized a new $100 million share repurchase program running through May 2029. The timing is notable because it adds an additional capital allocation lever while the company is still investing in commercial infrastructure and maintaining a stated focus on business development.

In practice, the authorization gives management flexibility to respond to valuation and cash flow conditions over multiple years rather than forcing a near-term pace. It also signals confidence in the durability of the earnings step-up implied by the updated 2026 outlook.

ANI Pharmaceuticals’ Valuation Context and Price Target Logic

At roughly 9.75x forward twelve-month earnings, ANIP trades well below the Zacks sub-industry multiple of 41.94x, the Zacks sector multiple of 20.32x, and the S&P 500 multiple of 21.43x. Over the past five years, the stock’s forward earnings multiple has ranged from 7.40x to 61.11x, with a median of 15.69x, placing today’s level closer to the low end of its own history.

The price target framework is also explicitly multiple-driven. The $85 target reflects 10.21x forward twelve-month earnings, which sits modestly above the current forward multiple. From here, the valuation looks “cheap” if execution sustains the Cortrophin trajectory, the retina franchise returns to growth as guided, and the generics cadence supports the raised outlook. The multiple can look “deserved” if competitive intensity and customer concentration pressure limit pricing power or slow the recovery path embedded in Iluvien expectations.

ANIP’s Zacks Rank

ANI Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report

Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

ANI Pharmaceuticals ANIP is leaning harder into its Rare Disease franchise as growth increasingly concentrates around Purified Cortrophin Gel. The next step is a sharper commercial push into acute gouty arthritis flares, which management is treating as a meaningful new demand pocket.

At the same time, the company is working to restore momentum in its retina franchise after a 2025 setback tied to market access. The setup creates a near-term spend cycle, but also clearer checkpoints investors can follow through 2026.

ANIP’s New Demand Pocket: Acute Gouty Arthritis Flares

The commercial expansion into acute gouty arthritis flares is being positioned as an emerging growth initiative for Cortrophin. The rationale is straightforward. Management sees a large, relatively untapped patient population and believes the current penetration level leaves room for sustained growth.

“Targeted execution” here is less about broad-based promotion and more about building a repeatable specialty playbook. The strategy emphasizes focused coverage and tighter field activity around the acute flare opportunity, with execution designed to translate interest into consistent starts rather than one-off wins.

ANI Pharmaceuticals’ Sales Force Buildout and Near-Term Spend

To support the acute gout initiative, ANI is deploying a dedicated sales force of about 90 people. That planned buildout matters for investors because it creates a visible near-term investment cycle in operating expenses.

The early signs of that spending already showed up in first-quarter 2026 trends. Adjusted selling, general and administrative expenses rose 12% year over year to $71.4 million, driven in part by initial marketing and recruitment spending tied to the acute gout commercial buildout. Investors should frame the cost increase as the front end of a growth effort, with expense momentum tracking headcount ramp, training, and field execution as the organization scales into the targeted acute gout channel.

ANIP’s Prefilled Syringe: A Practical Adoption Lever

ANI also has a practical adoption lever in the form of a prefilled syringe formulation for Cortrophin. The key point is usability. Management highlights improved ease of use as a factor that can reduce friction around starts and support wider uptake in the field.

Importantly, the uptake commentary is already tangible. The prefilled syringe has gained rapid traction and is cited as accounting for a majority of new patient starts. That framing keeps the focus on adoption mechanics, where a simpler format can reinforce the impact of a larger commercial footprint.

Story Continues

ANI Pharmaceuticals, Inc. PriceANI Pharmaceuticals, Inc. Price

ANI Pharmaceuticals, Inc. price | ANI Pharmaceuticals, Inc. Quote

ANI Pharmaceuticals’ Competitive Reality in ACTH Therapies

Competition is not theoretical in ACTH therapies. The primary competitor named is Acthar Gel, marketed by Keenova Therapeutics, and the market dynamic described is notable because both products are seeing momentum in sales growth.

For ANIP shareholders, that sets up a watch list centered on positioning and access dynamics. If both brands are expanding, the slope of growth can hinge on how consistently ANI converts targeted demand pockets, how effectively it supports access, and how competition influences share capture over time. Separately, competition across ophthalmology is also relevant to the broader story, where AbbVie ABBV and Regeneron Pharmaceuticals REGN are cited as key rivals through products used in overlapping markets.

ANIP’s Second Growth Vector From the Retina Franchise

ANI’s retina franchise is framed as a second growth vector, with Iluvien and Yutiq helping diversify revenue and reduce reliance on Cortrophin. In 2025, the combined Iluvien/Yutiq contribution was $74.9 million, though performance was pressured by market access challenges, including funding constraints affecting patient assistance programs for Medicare beneficiaries.

Management characterized 2025 as a “reset year,” and the response included consolidating Iluvien and Yutiq into a unified Iluvien brand promoted across diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment of the eye. The intention is to streamline promotion and support recovery as access conditions normalize.

ANI Pharmaceuticals’ 2026 Milestones to Watch

The 2026 setup includes several measurable markers. For Iluvien, sales are expected to recover with guidance of $78-$83 million, implying 4%-11% year-over-year growth. On the Generics side, management remains on track for a steady cadence of 10-15 new launches in 2026, reinforcing the segment’s role as a cash-flow foundation even if it is no longer the primary growth driver.

Investors also have discrete milestone checkpoints tied to the Harmony Biosciences HRMY licensing agreement. ANI received a $15 million upfront license fee and expects an additional $10 million in development milestones to be achieved in the second and third quarters of 2026. Taken together, Iluvien’s guided recovery range, the generics launch cadence, and the Harmony milestone timing give ANIP holders a practical scorecard for tracking execution as the Cortrophin acute gout push scales through 2026.

ANIP’s Zacks Rank

ANI Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report

Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

ANI Pharmaceuticals ANIP is reshaping its growth profile. In 2025, revenue surged on the back of a rare disease franchise that is becoming the company’s defining investment narrative. The key is Purified Cortrophin Gel, an ACTH-based injection that is increasingly central to both top-line expansion and the margin mix.

With 2026 guidance calling for rare disease to become the majority of sales, the next question for investors is what has to keep working for Cortrophin to deliver at scale.

ANIP’s Rare Disease Shift Is Now the Story

ANIP’s revenue momentum is increasingly skewed toward its Rare Disease and Brands segment, reflecting a portfolio tilt toward higher-margin specialty therapies. In fiscal 2025, total revenue was $883.4 million, up 43.8% year over year. Rare Disease and Brands contributed $484.0 million, or 54.8% of total revenue, versus $399.4 million, or 45.2%, from Generics and Other.

Within Rare Disease and Brands, Cortrophin Gel generated $347.8 million in 2025 revenue. The retina franchise Iluvien/Yutiq added $74.9 million, but Cortrophin remained the anchor product. This mix matters because it signals a shift in the durability of growth: performance is being driven less by a broad basket of products and more by a specialty platform with clearer strategic focus.

ANI Pharmaceuticals’ Cortrophin Growth Drivers in 2025

Cortrophin delivered nearly $348 million in 2025 revenue, up about 76% year over year. That increase was a major contributor to the company’s roughly 44% total revenue growth in 2025, reinforcing how tightly overall expansion is now tied to the rare disease franchise.

Rare disease revenue grew more than 80% year over year, underscoring Cortrophin’s outsized role in the model. The result is a growth engine that is not only larger, but also increasingly central to how ANIP is building its commercial strategy around specialty therapies.

ANIP’s 2026 Outlook for Cortrophin Sales

Management guided to 2026 Cortrophin Gel net revenue of $540 million to $575 million. That range sits inside a broader 2026 total net revenue outlook that was raised after the first quarter to $1.08 billion to $1.14 billion.

Mix expectations are just as important as the headline growth. Rare disease is expected to account for the majority of 2026 sales, roughly 60% by management’s framing. Hitting the midpoint of Cortrophin guidance implies that demand continues to broaden across specialties, access remains workable through payer dynamics, and the commercial buildout translates into incremental patient starts, especially in targeted indications such as acute gouty arthritis flares.

Story Continues

ANI Pharmaceuticals, Inc. PriceANI Pharmaceuticals, Inc. Price

ANI Pharmaceuticals, Inc. price | ANI Pharmaceuticals, Inc. Quote

ANI Pharmaceuticals’ Adoption Catalysts Across Specialties

A key part of the growth narrative is under-penetration in the addressable market, with adoption expanding across rheumatology, nephrology, and pulmonology. ANIP is pairing that demand opportunity with targeted commercial execution designed to translate interest into consistent prescribing behavior.

One centerpiece is a planned dedicated ~90-person sales force buildout focused on acute gouty arthritis flares, which management describes as a large and relatively untapped patient population. This is a specific go-to-market decision that aims to turn a narrower specialty footprint into broader utilization while keeping the strategy anchored in rare disease.

Product experience is also part of the adoption story. The prefilled syringe formulation has improved ease of use and has already gained rapid traction, accounting for a majority of new patient starts. In specialty markets, that kind of friction reduction can matter, particularly when the goal is to accelerate uptake across multiple physician channels.

ANIP’s Q1 2026 Check-In and What It Signals

First-quarter 2026 results extended the Cortrophin momentum, with net revenues rising 42% year over year to $75.1 million. Rare Disease and Brands revenue grew 36% to $128.2 million, supported by both Cortrophin and Iluvien contributions.

Management emphasized that Cortrophin’s quarter reflected seasonality tied to insurance re-verifications. The process took longer early in the quarter due to higher patient volume at physician offices. Weather-related office closures in some regions also contributed.

For investors, the takeaway is to be careful about extrapolating a single quarter’s cadence into a full-year run rate. The quarter still showed strong year-over-year growth, but the commentary highlights how administrative timing and access mechanics can influence quarterly variability even in an expanding franchise.

ANI Pharmaceuticals’ Key Risks to Monitor in Rare Disease

Competitive pressure is building in the rare disease space, and Cortrophin’s primary competitor is Acthar Gel, marketed by Keenova Therapeutics. Acthar is described as experiencing similar momentum in sales growth, keeping competitive dynamics relevant as ANIP expands in targeted markets.

More broadly, competing with larger pharmaceutical companies can shape pricing, access, and positioning over time. In ophthalmology, AbbVie ABBV competes through Ozurdex, while Regeneron Pharmaceuticals REGN is a major presence with Eylea and Eylea HD in diabetic macular edema. These companies have scale and entrenched commercial footprints, which can raise the bar for differentiated execution in specialized markets.

ANIP’s Zacks Rank

ANI Pharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard S&P 500 Growth ETF (Symbol: VOOG) where we have detected an approximate $370.1 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 309,275,829 to 313,850,829). Among the largest underlying components of VOOG, in trading today Palantir Technologies Inc (Symbol: PLTR) is up about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Welltower Inc (Symbol: WELL) is up by about 2%. For a complete list of holdings, visit the VOOG Holdings page » The chart below shows the one year price performance of VOOG, versus its 200 day moving average:

Looking at the chart above, VOOG's low point in its 52 week range is $62.7167 per share, with $85.3465 as the 52 week high point — that compares with a last trade of $80.95. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».

Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.

Click here to find out which 9 other ETFs had notable inflows »

Further VOOG Research:

VOOG VideosVOOG Historical Stock PricesAnalyst Least Favorites

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

AstraZeneca PLC (NYSE:AZN) was among the stocks Jim Cramer discussed on Mad Money, along with the recent sell-off in the market. Cramer highlighted the company's stock transfer to the NYSE, as he remarked:

This morning, the pharmaceutical company, AstraZeneca, rang the opening bell to celebrate their transfer to the New York Stock Exchange. It's the largest transfer in the history of the 234-year-old institution. The British pharma stock has rallied 30% over the past 12 months. It's been a good one, and it's very much on track to hit the ambitious long-term financial targets they rolled out in 2024. That's largely thanks to the company's booming oncology business.

A stock market graph. Photo by Alesia Kozik on Pexels

AstraZeneca PLC (NYSE:AZN) manufactures prescription medicines for oncology, cardiovascular, respiratory, and rare diseases. During the January 30 episode, a caller noted that they were considering selling their position in the company's stock for a profit and buying ABBV. Cramer replied:

I like AstraZeneca very much. And that cancer franchise turned out to be a lot stronger than I thought. I think you should hold onto that. AbbVie reports this week. I expect a very good quarter. I like the dividend, but I think AstraZeneca has got a better portfolio at this very moment.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.

View Comments